Nastech begins phase 1 study of insulin nasal spray for diabetes

By E. Janene Geiss

Philadelphia, Sept. 19 - Nastech Pharmaceutical Co. Inc. announced Tuesday the start of a phase 1 pharmacokinetic study designed to evaluate the safety, bioavailability and glucose response of Nastech's proprietary, rapid acting intranasal insulin formulation.

The study will compare Nastech's intranasal formulation to an approved injectable product and to a recently approved new dosage form, Exubera (insulin human [rDNA origin]) inhalation powder, the Bothell, Wash., pharmaceutical company said in a news release.

Nastech said its insulin nasal spray could provide patients with a convenient, needle-free alternative while avoiding possible pulmonary side effects or long-term toxicity associated with the inhalation of insulin.

This study is the first of several studies to select the formulation and determine the optimal insulin nasal spray dose that will be used to conduct subsequent safety and efficacy studies. Pharmacokinetic and pharmacodynamic parameters will be evaluated as well as tolerability of the insulin nasal spray doses.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.